High Potency API Contract Manufacturing Market is expected to be worth US$ 16 billion by 2032 | FMI

The Global High Potency API Contract Manufacturing Market was worth US$ 8 billion in 2022 and is expected to be worth US$ 16 billion by 2022-2032, at a CAGR of 7%. Because of the increasing frequency of cancer cases worldwide, the use of HPAPIs is increasing, which is driving the market.

Rising breakthroughs in high potency API (HPAPI) manufacturing technologies, combined with the quest for more effective drugs to improve patient outcomes, have significantly increased the number of HPAPIs in development pipelines, accelerating industry growth. Furthermore, a rising tendency in outsourcing operations due to greater risk management, lower costs, and the availability of modern ways to HPAPI controls has fueled growth.

From 2017 to 2021, the industry experienced noteworthy growth, registering a value CAGR of 5% and closing at US$ 6.5 Billion. The sector is seeing profitable expansion, and suppliers are quickly investing in new facilities and expanding their R&D laboratories. Piramal Pharm Solutions, for example, plans to expand its API and HPAPI research and manufacturing facilities in Michigan with increased capacity and additional capabilities in December 2020. To fulfill predicted demand, which included prospective possibilities, the corporation spent US$ 32 million in the plant. HPAPI regulatory oversight has grown stronger over time.

Request a Sample of this Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-15786

Key Takeaways from the Market Study

  • FMI projects the global high potency API Contract Manufacturing market to expand at a 7% value CAGR by 2032
  • The global High Potency API Contract Manufacturing market is estimated at a market value of US$ 8 Billion
  • The global high potency API contract manufacturing market is expected to garner a market value of US$ 16 Billion
  • By application, oncology to experience major HPAPI contract manufacturing activities, yielding 63% of global revenue

“Demand for contract manufacturing of HPAPIs has expanded dramatically in recent years, and is one of the primary drivers of the global HPAPI market, owing to a rising number of prospective phase 3 drug candidates.”Says an analyst at FMI 

Market Competition

Piramal Pharma Solutions, Lonza, Catalent, Inc., VxP Pharma, Inc., Pfizer CentreOne, Gentec Pharmaceutical Group, AbbVie, Aurigene Pharmaceutical Services Ltd., CordenPharma International and Curia Global, Inc., are some prominent High Potency API Contract Manufacturing manufacturers.

  • In June 2021, Lonza, for example, spent USD 21.5 billion in its Nansha, China, plant to enhance its API development and manufacturing capacity. Three 1,000 L GMP trains totalling 12 cu. ft. of reactor volume m. Additional expenditures will be made, as well as new research and GMP facilities capable of creating small-scale batches of highly effective APIs.

Contact our Market Research Specialist: https://www.futuremarketinsights.com/ask-question/rep-gb-15786

Key Segments Profiled in the High Potency API Contract Manufacturing Market Industry Survey

High Potency API Contract Manufacturing Market by Product Type:

  • Innovative
  • Generic

High Potency API Contract Manufacturing Market by Synthesis:

  • Synthetic
  • Biotech

High Potency API Contract Manufacturing Market by Application:

  • Oncology
  • Hormonal Disorders
  • Glaucoma
  • Others

Buy Now/Purchase: https://www.futuremarketinsights.com/checkout/15786

High Potency API Contract Manufacturing Market by Dosage Form:

  • Injectable
  • Oral Solids
  • Creams
  • Others

About Future Market Insights (FMI) 

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedInTwitterBlogs

About the Author

Nikhil Kaitwade

Associate Vice President at Future Market Insights, Inc. has over a decade of experience in market research and business consulting. He has successfully delivered 1500+ client assignments, predominantly in Automotive, Chemicals, Industrial Equipment, Oil & Gas, and Service industries.
His core competency circles around developing research methodology, creating a unique analysis framework, statistical data models for pricing analysis, competition mapping, and market feasibility analysis. His expertise also extends wide and beyond analysis, advising clients on identifying growth potential in established and niche market segments, investment/divestment decisions, and market entry decision-making.
Nikhil holds an MBA degree in Marketing and IT and a Graduate in Mechanical Engineering. Nikhil has authored several publications and quoted in journals like EMS Now, EPR Magazine, and EE Times.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these